Protalix BioTherapeutics, Inc. (DE) (PLX) News
Filter PLX News Items
PLX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PLX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest PLX News From Around the Web
Below are the latest news stories about PROTALIX BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate PLX as an investment opportunity.
US Penny Stocks: Arbe Robotics And 2 More Promising PicksAs the U.S. stock market navigates a period of volatility marked by rising Treasury yields and shifting economic data, investors are increasingly exploring alternative investment avenues. Penny stocks, often representing smaller or newer companies, continue to attract interest due to their potential for value and growth that larger firms might overlook. Despite being an older term, penny stocks remain relevant for those seeking opportunities in under-the-radar companies with promising... |
Protalix BioTherapeutics Issues 2025 Letter to StockholdersProtalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders. |
EMA validates Chiesi and Protalix’s dose variation for Fabry diseaseThe proposed regimen suggests a dose of 2 mg/kg body weight administered every four weeks for adults. |
Promising US Penny Stocks To Watch In December 2024As U.S. markets experience fluctuations amid inflation data and interest rate speculations, investors are keenly observing potential opportunities across various sectors. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired with strong financials. |
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfaChiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, and Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that the European Medicines Agency (EMA) has validated the |
PLX: Self-Sustaining Rise to Lead in Renal Rare DiseaseBy John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Third Quarter 2024 Financial and Operational Review Protalix Biotherapeutics, Inc. (NYSE:PLX) announced third quarter 2024 financial and operational results in a November 14 th , 2024 press release and in the filing of Form 10-Q . The reports were followed by a conference call which discussed recent achievements, clinical |
Protalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ...Protalix BioTherapeutics Inc (PLX) reports a 75% increase in revenue from selling goods and outlines future clinical trial plans. |
Protalix: Q3 Earnings SnapshotHACKENSACK, N.J. (AP) — Protalix BioTherapeutics Inc. PLX) on Thursday reported earnings of $3.2 million in its third quarter. On a per-share basis, the Hackensack, New Jersey-based company said it had profit of 3 cents. |
Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business ResultsProtalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2024, and provided a business and clinical update. |
Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended September 30, 2024 and provide a business and clinical update on November 14, 2024. |